MOLN

Molecular Partners AG (NASDAQ:MOLN) is a Swiss clinical-stage biopharmaceutical company founded in 2004 and headquartered in Schlieren, Switzerland. The company went public on NASDAQ in June 2021. Molecular Partners specializes in developing therapeutic proteins using its proprietary <b>DARPin</b> (Designed Ankyrin Repeat Proteins) technology platform, which creates alternatives to traditional antibodies for treating cancer and other diseases. The company has established strategic partnerships with major pharmaceutical companies including Novartis, Amgen, and AbbVie, and maintains a strong financial position with substantial cash reserves funding operations into 2027.